Tardío Juan C, Cambero Olivia, Sánchez-Estévez Carolina, Sánchez-García Ana B, Angulo Fernando, Moreno Amalia
Department of Pathology, University Hospital of Fuenlabrada, Madrid, Spain.
Int J Gynecol Pathol. 2019 Jan;38(1):11-16. doi: 10.1097/PGP.0000000000000467.
Roche cobas 4800 human papillomavirus (HPV) test is an automated real-time polymerase chain reaction-based system that allows the simultaneous detection of 14 human papillomavirus high-risk (HR-HPV) genotypes. This test is Food and Drug Administration approved since 2011 for HPV determination in liquid-based cytologic samples, but a clinically validated technique for formalin-fixed, paraffin-embedded (FFPE) tissue specimens is presently not commercially available. In our laboratory, we have developed an HPV detection procedure in FFPE tissue by cobas 4800 HPV test. In order to validate our method, we retrospectively studied 165 FFPE cervical biopsy and conization specimens with varied diagnoses from our files. In 50 of them, we contrasted the results with those obtained from simultaneous liquid-based cytologies from the same patients. Finally, seeking the possible complementary clinical usefulness of the procedure, we compared the HPV genotypes detected in cervical intraepithelial neoplasia grade 1 (CIN1)-diagnosed biopsies from 20 patients with a subsequent high-grade CIN (CIN2+) diagnosis with those from another group of 20 patients without a subsequent CIN2+ diagnosis. Eighty-seven percent of the assays provided informative results. HR-HPV was detected in 28 of 32 (88%) invasive cervical squamous carcinomas. Coincidental HR-HPV genotypes were obtained in 32 of 50 (64%) cases with simultaneous cervical biopsy and liquid-based cytologic samples. A significant higher risk of progression to CIN2+ was found when HPV16 (P=0.022) or any HR-HPV genotype (P=0.037) was detected in CIN1 biopsies. The reported procedure provides an automated, technically time-saving, easy to integrate into laboratory routine, and reliable method of HR-HPV determination in FFPE specimens.
罗氏 cobas 4800 人乳头瘤病毒(HPV)检测是一种基于实时聚合酶链反应的自动化系统,可同时检测 14 种人乳头瘤病毒高危(HR-HPV)基因型。自 2011 年起,该检测已获美国食品药品监督管理局批准,用于液基细胞学样本中的 HPV 检测,但目前尚无经过临床验证的针对福尔马林固定、石蜡包埋(FFPE)组织标本的技术可供商业使用。在我们实验室,我们通过 cobas 4800 HPV 检测开发了一种用于 FFPE 组织的 HPV 检测方法。为验证我们的方法,我们回顾性研究了我们档案中 165 份诊断各异的 FFPE 宫颈活检和锥切标本。其中 50 份标本,我们将结果与同一患者同时进行的液基细胞学检测结果进行了对比。最后,为探寻该方法可能具有的临床互补实用性,我们比较了 20 例诊断为宫颈上皮内瘤变 1 级(CIN1)的活检标本中检测到的 HPV 基因型与随后诊断为高级别 CIN(CIN2+)的情况,以及另一组 20 例未随后诊断为 CIN2+的患者的情况。87%的检测提供了有用信息。在 32 例浸润性宫颈鳞状癌中有 28 例(88%)检测到 HR-HPV。在 50 例同时进行宫颈活检和液基细胞学样本检测的病例中,有 32 例(64%)获得了一致的 HR-HPV 基因型。当在 CIN1 活检中检测到 HPV16(P = 0.022)或任何 HR-HPV 基因型(P = 0.037)时,发现进展为 CIN2+的风险显著更高。所报告的方法提供了一种自动化、技术上节省时间、易于融入实验室常规操作且可靠的 FFPE 标本中 HR-HPV 检测方法。